Vaccination in Individuals with Multiple Sclerosis – Part I

Basit Öğe Kaydı
dc.authorscopusid55890614200
dc.authorscopusid57195979263
dc.authorscopusid57205507893
dc.authorscopusid57225924847
dc.authorscopusid55826416500
dc.authorscopusid58223287900
dc.authorscopusid26666613100
dc.contributor.authorÇınar B.P.
dc.contributor.authorTuncer A.
dc.contributor.authorBilge N.
dc.contributor.authorBünül S.D.
dc.contributor.authorGözübatık-çelik R.G.
dc.contributor.authorÇiftçi E.D.
dc.contributor.authorGenç G.
dc.date.accessioned2024-03-09T19:40:02Z
dc.date.available2024-03-09T19:40:02Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractMultiple sclerosis (MS) is an autoimmune and demyelinating disease of the central nervous system. It is a chronic disease, and in the evaluation of all other health and vital processes, decisions should be made by considering the disease process and the drugs used by the patient. Since vaccination can be performed at every stage of life, from childhood to adulthood, immune system activity, except where it is characteristic of the vaccine, should be reviewed in patients with MS. In this review, the applications of different vaccines in individuals with MS are discussed in two separate sections. © 2023 by Turkish Neurological Society Turkish Journal of Neurology published by Galenos Publishing House.en_US
dc.identifier.doi10.4274/tnd.2023.62592
dc.identifier.endpage11en_US
dc.identifier.issn1301-062X
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85156204478en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage2en_US
dc.identifier.trdizinid1177074en_US
dc.identifier.urihttps://doi.org/10.4274/tnd.2023.62592
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1177074
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1639
dc.identifier.volume29en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherTurkish Neurosurgical Societyen_US
dc.relation.ispartofTurk Noroloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultiple sclerosis; safety; vaccinationen_US
dc.subjectalemtuzumab; azathioprine; BCG vaccine; cyclophosphamide; dimethyl fumarate; diphtheria pertussis tetanus vaccine; diphtheria tetanus vaccine; fingolimod; glatiramer; hepatitis A vaccine; hepatitis B vaccine; influenza vaccine; measles mumps rubella vaccine; myelin basic protein; natalizumab; ocrelizumab; ofatumumab; ozanimod; rabies vaccine; rituximab; teriflunomide; tetanus toxoid; anaphylaxis; antibody response; apoptosis; asthma; bacteremia; bacterial arthritis; bone marrow transplantation; cardiovascular disease; chronic fatigue syndrome; chronic kidney failure; fatigue; headache; hemodialysis; Hepadnaviridae; hepatitis B; human; immune response; immune system; immunity; immunization; immunogenicity; immunosuppressive treatment; leprosy; mastoiditis; multiple sclerosis; myalgia; obesity; osteomyelitis; pneumococcal infection; post exposure prophylaxis; recombinant DNA technology; Review; Streptococcus pneumoniae; thrombocytopenia; tuberculosis; urticaria; vaccination; viremiaen_US
dc.titleVaccination in Individuals with Multiple Sclerosis – Part Ien_US
dc.title.alternativeMultipl Skleroz Tanılı Bireylerde Aşılama – Bölüm Ien_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1639.pdf
Boyut:
165.61 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu